World Antimalarial Resistance Network



To create a global, comprehensive, and inclusive network, providing qualityassured information on antimalarial drug resistance.



WASHINGTON DC • NEW DELHI

ACTs CURRENTLY EFFECTIVE, BUT.....


HOW CAN WE SUSTAIN MAXIMUM USEFUL THERAPEUTIC LIFE OF ACTs?

HOW CAN WE STAY AHEAD OF THE EVOLUTIONARY CURVE?

HISTORY OF WARN

- INFORMAL MEETINGS
 - ASTMH, 2004, 2005
 - MIM 2005
- PLANNING MEETING
 - BMGF, October 2006
- SUMMARY PAPERS PUBLISHED
 - Malaria Journal, SEPT 2007
- 1 YEAR PLANNING GRANT
 BMGF funded, Sept 2007
- IMPLEMENTATION GRANT SUBMISSION
 July, 2008

WARN PLANNERS 2006/2008




WHAT HAVE WE LEARNED FROM "OLD" DRUGS?

• RESISTANCE ARISES RARELY, BUT SPREADS RELATIVELY QUICKLY

CLINICAL TREATMENT FAILURE IS THE LAST STEP IN
 A LONG SERIES OF CHANGES

HOW CAN WE FIT THIS TOGETHER?




EARLY WARNING OF RESISTANCE

- SLOWER TIME TO CLEAR PARASITES
- IN VITRO INCREASES IN IC₅₀ VALUE

• INCREASING PREVALENCE OF "RESISTANT" ALLELES

TOOLS AND PARTNERSHIP



OVERVIEW OF PLAN


WEB BASED, OPEN ACCESS (WITH REGISTRATION)


FREELY AVAILABLE TOOLS FOR DATA ORGANIZATION INPUT ANALYSIS

GATEKEEPERS TO FACILITATE DATA UPLOAD (and assure quality


FREELY AVAILABLE <u>TOOLS</u> FOR DATA OUTPUT MAP BASED GRAPHICAL TABULAR **OVERVIEW OF PLAN**

- PROSPECTIVELY FOCUSED
- INDIVIDUAL PATIENT/ISOLATES RECORDS
- COMMON PROTOCOLS FOR QUALITY ASSURANCE
- STRONG LINKS WITH OTHER GROUPS INVOLVED IN SURVEILLANCE
- FOUR LINKED MODULES CLINICAL EFFICACY PHARMACOLOGY IN VITRO SUSCEPTIBILITY OF ISOLATES MOLECULAR MARKERS






THE CENTRAL OUTCOME MEASUREMENT



CLINICAL EFFICACY STUDIES

- WHO GUIDELINES, 28 DAY+ FOLLOW UP
- PARTICIPATION OF SENTINAL SITES
- BASIC DATA ON STUDY SITE
- STANDARDIZED REPORTING OF KEY
 VARIABLES ON INDIVIDUAL PATIENTS
 - Patient and study
 - Date
 - Treatment received
 - Initial species of infection
 - Last day of follow up
 - Outcome on last day


25 COUNTRIES OF ORIGIN- CLINICAL STUDY DATA



DEMONSTRATION OF UTILITY

STUDY SITE	# PATIENTS
SMRU:	11,399
Uganda and Burkino Faso	5,539
Epicentre/MSF	1,590
Other	10,259
TOTAL	25,214

Ric Price Grant Dorsey Liz Ashley Ambrose Talisuna 25 Countries Varied Study Designs Duration of follow up Pf and Pv efficacy studies Recoding of LPF and LCF



PK ASSESSMENT IN AT RISK GROUPS


DID FAILURE RESULT FROM INADEQUATE DRUG LEVELS?


- INFANTS, UNDER 5s
- PREGNANT WOMEN
- MALNOURISHED
- HIV+/AIDS

COINFECTION WITH OTHER PATHOGENS

PHARMACOLOGY NETWORK

- 5 REGIONAL ANALYSIS LABS
 - 1 ASIA
 - 3 AFRICA
 - 1 LATIN AMERICA
- LINKED BY COMMON QC CRITERIA
- SHARED TEST REAGENTS
- COORDINATED WITH CLINICAL ASSESSMENTS
 - DRUG LEVELS ON DAY 7





PARASITE PHENOTYPING NETWORK


- REGIONAL REFERENCE LABS/ QC SOURCE
- ANALYZE CURRENT PATIENT ISOLATES
- AGREED PROTOCOL ON TIME, MEDIA, PARASITEMIA, HEMATOCRIT
- AGREED QC
 - POSITIVE AND NEGATIVE CONTROLS
 - STANDARD REFERENCE CLONES
 - STANDARD DRUGS
- VARIOUS ANALYSIS METHODS, BUT STRICT ADHERENCE TO CHOSEN PROTOCOL

DATA COMPARABLE OVER TIME FROM ONE LAB TO NEXT!

PARASITE ISOLATES WITH DECREASED DRUG SENSITIVITY PHENOTYPE


PRESERVED AND SHARED CANDIDATES FOR INTENSIVE GENETIC ANALYSIS

IDENTIFICATION OF LOCI ASSOCIATED WITH RESISTANCE TO EACH PARTNER IN ACT



IDENTIFYING MOLECULAR MARKERS

- VERIFIED PHENOTYPE-DECREASED DRUG SENSITIVITY
 GENOME/TRANSCRIPT COMPARISONS SINGLE NUCLEOTIDE POLYMORPHISMS (SNPs) COPY NUMBER VARIATION TRANSCRIPTION PROFILE?
- COMPARISON AMONG STRAINS FROM DIFFERENT REGIONS WITH SAME PHENOTYPE
- VERIFIED MOLECULAR MARKERS FOR COMPONENTS OF ACTs



WHAT CAN WE EXPECT FROM NETWORK?

FOR NEW COMBINATION DRUGS

GEOGRAPHIC PATTERNS TEMPORAL PATTERNS

CLINICAL EFFECTIVENESS

 CORRECT DOSES FOR AT RISK GROUPS

• PARASITE DRUG PHENOTYPES, IN VIVO CORRELATES?


 MOLECULAR CORRELATES OF RESISTANCE? **IMPACT OF DATABASE**

- TIMELY EVIDENCE ON DRUG EFFICACY
- TOOLS FOR ANALYSIS AND OUTPUT
 INCENTIVES FOR PARTICIPATION
- REGIONAL OUTPUT/ANALYSIS OF DATA
- IMPROVED COMMUNICATION OF DRUG EFFICACY TO POLICY MAKERS


IMPLEMENTATION CHALLENGES


- Integration with WHO
- Coordination with
 - Other groups engaged in malaria surveillance
 - MMV
 - Networks/regional data centers
- Adaptation to local/regional needs
- Establishing relations with MoHs
- Sustainable funding

SIMPLE ANALYSIS OF TREATMENT OUTCOME





SURVIVAL ANALYSIS OF INDIVIDUAL PATIENT DATA





...BUT NEW COMBINATIONS ARE IN USE OR IN TRIALS





FIRST REPORTS OF CHLOROQUINE RESISTANCE IN AFRICA

